Copertura documentale

Il Quality Gate pubblico registra 26 supporti documentali, 3 fonti indipendenti e 9 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary? — Crossref
• Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy — Crossref
• Uncovering Immune Cell–Specific lncRNAs as Anti-PD-1 Response-Associated Markers in Breast Cancer — Crossref
• Efficacy of adding neoadjuvant pembrolizumab to standard chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis of real-world studies — Crossref
• Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape — Europe PMC
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — ClinicalTrials.gov
• Spatial architecture of tumor-infiltrating lymphocytes adds predictive value beyond stromal TIL density for neoadjuvant response in triple-negative breast cancer — Crossref
• Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes — Crossref
• Prevalence and Determinants of Depression, Anxiety, and Quality of Life in Patients With Breast Cancer in Saudi Arabia: A Focus on Adjuvant Pharmacotherapy — Crossref
• Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer — Crossref
• Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer — Crossref
• Sacituzumab-govitecan plus pembrolizumab: redefining first-line therapy in PD-L1-positive advanced triple-negative breast cancer. — Europe PMC

Collegamenti nel Knowledge Graph

• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) — uses intervention
• Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer — uses intervention
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 — uses intervention
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — uses intervention
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — uses intervention
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — uses intervention
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors — uses intervention
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer — uses intervention
• Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer — uses intervention
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer — uses intervention
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors — uses intervention
• Breast Cancer Study of Preoperative Pembrolizumab + Radiation — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 97/100 · ultimo aggiornamento Settembre 30, 2026